scholarly journals Stem Cells in Treatment of Coronary Heart Disease and Its Monitoring: Tissue Engineering and Clinical Evaluation

2018 ◽  
Author(s):  
Rakesh Sharma
Keyword(s):  
Tissue Engineering ◽  
Stem Cells ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Clinical Evaluation

scholarly journals Cellular therapy of coronary heart disease: a review of concepts, limitations, prospects. Part Two. Stem cells, prospects of cullular therapy

Cor et Vasa ◽  
2006 ◽  
Vol 48 (6) ◽  
pp. 234-241
Author(s):  
Martin Pěnička ◽  
Petr Widimský ◽  
Tomasz Siminiak ◽  
Otto Lang ◽  
Karol Čurila ◽  
...  
Keyword(s):  
Stem Cells ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Cellular Therapy

scholarly journals Stem cells in the treatment of patients with coronary heart disease. Part I

2011 ◽  
Vol 10 (2) ◽  
pp. 122-128 ◽  
Author(s):  
N. S. Zhukova ◽  
I. I. Staroverov
Keyword(s):  
Stem Cells ◽  
Coronary Heart Disease ◽  
Stem Cell ◽  
Heart Disease ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Myocardial Damage ◽  
Cellular Cardiomyoplasty ◽  
Modern Methods ◽  
Death Causes

Heart failure (HF) is one of the leading death causes in patients with myocardial infarction (MI). The modern methods of reperfusion MI therapy, such as thrombolysis, surgery and balloon revascularization, even when performed early, could fail to prevent the development of large myocardial damage zones, followed by HF. Therefore, the researches have been searching for the methods which improve functional status of damaged myocardium. This review is focused on stem cell therapy, a method aimed at cardiac function restoration. The results of experimental and clinical studies on stem cell therapy in coronary heart disease are presented. Various types of stem cells, used for cellular cardiomyoplasty, are characterised. The methods of cell transplantation into myocardium and potential adverse effects of stem cell therapy are discussed.

scholarly journals Anisotropic microfibrous scaffolds enhance the organization and function of cardiomyocytes derived from induced pluripotent stem cells

2017 ◽  
Vol 5 (8) ◽  
pp. 1567-1578 ◽  
Author(s):  
Maureen Wanjare ◽  
Luqia Hou ◽  
Karina H. Nakayama ◽  
Joseph J. Kim ◽  
Nicholas P. Mezak ◽  
...  
Keyword(s):  
Stem Cells ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Myocardial Tissue ◽  
Tissue Constructs ◽  
Induced Pluripotent ◽  
And Function

Engineering of myocardial tissue constructs is a promising approach for treatment of coronary heart disease.

Clinical evaluation of the Sthaulyahara effect of Haritaki and Amalkai based on the principle of Hrasa Hetur Visheshascha

2018 ◽  
Vol 3 (3) ◽  
Author(s):  
Shruti Hiremath ◽  
Umapati Baragi ◽  
M. R. Sajjanshetty
Keyword(s):  
Blood Pressure ◽  
Adverse Effect ◽  
Coronary Heart Disease ◽  
Clinical Trials ◽  
Heart Disease ◽  
Clinical Evaluation ◽  
Statistical Significance ◽  
Practical Evaluation ◽  
Group A ◽  
Group B

Sthoulya is one of the most effective disease which affects someone social, physical and mental features. As per modern view, it is a precursor to coronary heart disease, high blood pressure, diabetic mellitis and osteoarthritis which have been recognised as the leading killer diseases of the millennium. Sthoulya is a state of increased Vikruta Vruddhi of Medodhatu. It is one of the Santarponottha Vikaras where a physician needs to apply the principle of Vishesha which can restore the unhealthy increase of components to the previous undiseased form. The drug Haritaki and Amalaki are having Laghu and Rooksha Guna which are opposite Gunas to that of the Sthoulya. Objectives - Practical evaluation of the Sthaulyahara effect of Haritaki and Amalkai based on the principle of Hrasa Hetur Visheshascha. Results - 60 patients (92%) had completed the trial, no adverse effect were reported. Both the groups had improved in the clinical trials, overall statistical significance was observed in the scores of both the groups. Discussion - By this statistical result we can concluded that Group A patients were more releived than Group B who were administered Haritaki Choorna. The hypothesis decided for the study was ‘Vishesha’ is the prime cause for Hrasa.Here it was clear that Vishesha applied was Guna Vishesha. Here significant results itself shows that Vishesha has done its role in reducing the obesity (Hrasa) in better way in both the Groups.

Autologous Bone Marrow Stem Cells (ABMC) for Cardiormyoplasty in 15 Patients with Acute and Chronic Myocardial Disease (ACMD) in Colombia.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4225-4225
Author(s):  
Francisco Cuéllar-Ambrosi ◽  
Juan Manuel Senior-Sánchez ◽  
Oscar Velásquez-Uribe ◽  
Claudia Navas-Rios ◽  
Juan Luis Londoño-Blair ◽  
...  
Keyword(s):  
Heart Failure ◽  
Stem Cells ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Ejection Fraction ◽  
Exercise Capacity ◽  
Autologous Bone Marrow ◽  
Permanent Disability ◽  
Chronic Coronary Heart Disease

Abstract Introduction: ACMD disease accounts for 50% of all cardiovascular deaths and is the leading cause of congestive heart failure as well as premature permanent disability in workers. Unfortunately no medication or procedure has shown efficacy in replacing myocardial tissue or neovascularization. Some clinical human trials indicate that ABMC transplantation improves cardiac function and is feasible, safe and beneficial. We report the first experience in Colombia with this type of therapy Methodology: This is the six months follow-up of 15 patients 23 - 60 years-old, 10M/5F with: A. an extensive, viability absence, acute myocardial infarction of anterior myocardial wall, 10 patients, with ejection fraction ≤ 40% that received standard postinfarction medical treatment, successful coronary percutaneous intervention and after intracoronary transfer of G-CSF mobilized ABMC, CD34 range 15–20 in millions. B. Five patients with chronic coronary heart disease and/or severe ischemic heart failure without option for standard revascularization therapies recibed epicardic implantation of G-SCF mobilized ABMC, CD34 range 14.5–19 in millions. Results: It was demonstrated in both groups: improvement in the mean ejection fraction from 29.44±3.36% before to 45±14,97% (p<0.001) after six months the exercise capacity increased in meaningful form evidenced by mean increase in the six minutes test from 295.07±66.04ms before to 648.4±93.15 ms after six months (p<0.001), the treadmill exercise time and the functional capacity in Mets from a mean of 4,8±1.02 before to 12.8±2.59 (p<0.001). there were significant changes in the myocardial perfusion at six months follow-up by nuclear images at diagnosis Figure Figure and 6 months later Figure Figure There were no presented complications related to the Cellular Transplant or the utilization of the G-CSF. Conclusions: This is the first experience in Colombia with stem cells for intracoronary and epicardic cardiomyoplasty in acute and chronic coronary heart disease. It was observed functional recovery of the left ventricle, improvement in the exercise capacity without adverse effects or complications related to this therapy. In patients with ACMD, treatment with G-CSF to mobilize ABMC is feasible and safe and seems to be effective under clinical conditions. The therapeutic effect might be attributed to ABMC-associated promotion of myocardial regeneration and neovascularization.

Sign in / Sign up

Export Citation Format

Share Document